Navigation Links
ForteBio Launches Dip and Read(TM) Immunogenicity Assay Kit for Rapid Detection of Anti-Drug Antibodies
Date:9/16/2009

MENLO PARK, Calif., Sept. 16 /PRNewswire/ -- ForteBio(R), Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, announced today that it has launched the new Dip and Read Immunogenicity Assay Kit for rapid detection of anti-drug antibodies (ADA) for use on the company's Octet(R) platform. The new assay kit provides life science researchers with new levels of throughput, speed and flexibility for measuring immune response to a therapeutic drug, an integral part of drug development.

"Traditional methods for anti-drug antibody detection can be time-consuming, insensitive and labor-intensive, and can result in low throughput," said Christopher Silva, ForteBio's vice president of marketing. "ForteBio's new Dip and Read Immunogenicity Assay Kit overcomes these limitations, providing the needed sensitivity, increased drug tolerance and flexibility to detect both high- and low-affinity ADA. It accomplishes this by leveraging the Octet platform's real-time, label-free detection technology to essentially automate the relevant processing steps and eliminate any plate-washing components."

The Dip and Read Immunogenicity Assay Kit's protocols work across many drug types, including antibodies, proteins and peptides. The assay kit provides biosensors and basic reagents to run two different assay configurations - an enzyme-linked bridging assay and a direct binding assay - for use with human, primate and other animal serum and plasma samples.

ForteBio's Octet system is based on the company's proprietary BioLayer Interferometry (BLI) technology, in which optical biosensors measure multiple interactions in parallel, without the use of detection reagents. The platform includes the Octet QK384 system, which enables 384-well detection, 16-channel simultaneous readout with two plate positions, biosensor regeneration and re-racking, and automation capabilities for increased cost-efficiencies and throughput, as well as faster time to results. The Octet instrumentation software has optional FDA 21 CFR part 11 compliance tools required by GLP laboratories.

About ForteBio, Inc.

ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.


'/>"/>
SOURCE ForteBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ForteBio, Inc. to Present at Thomas Weisel Partners Healthcare Conference 2009
2. ForteBio Launches New Biosensor for Kinetic Analysis and Screening of Human IgG Antibodies
3. Worlds First Emergency Medical Information Franchise Launches GPS Tracking Device
4. Affinion Security Center Launches Benefits to Help Detect and Resolve Medical Identity Theft
5. Autism Support Network Launches Enhanced Features, Adds Thousands of New Members Globally
6. Forterus Inc. Launches Updated, Improved Web Site
7. Loadstar Sensors Launches DI-1000z - Wireless Load Cell Interface
8. Kaiser Permanente Introduces New Ad, Re-launches Two Previous Ads
9. HIPAA.com Launches HIPAA TV
10. Veterinarian Group Launches New Website to Help Pet Owners With Medical Advice and the Best Vet-Approved Products
11. Senior Living Residences Launches Innovative Nutrition Program to Promote Cognitive Health and Lower the Risk of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... Society (ONS) wanted to create a communications platform that positions them as the ... Elliance and ONS reinvented their online publication as an always-on, always-fresh news, views ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro ... their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is ... Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation ... and college Bible teacher residing in North Carolina with his wife, Anna Marie. He ... them with six grandchildren. David is also the author of “Shadow and Substance.” , ...
(Date:3/23/2017)... ... 2017 , ... The physicians of KSF Orthopaedic Center PA are proud to ... location is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 ... provide patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of Fame” recognizes the ... acts have had a significant impact on the careers of all others involved. ... Inc. was inducted into the MBI’s Hall of Fame. The induction took place during ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the ... Strategies" report to their offering. ... Pain Management in the ... their physical pain, emphasizing consumer survey analysis, including trends over ... adults who have selected illnesses/conditions strongly associated with physical pain ...
(Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology: